Feature
What have we learnt from Vioxx?
BMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39024.487720.68 (Published 18 January 2007) Cite this as: BMJ 2007;334:120
Related articles
- News Published: 22 March 2007; BMJ 334 doi:10.1136/bmj.39157.476910.DB
- Analysis Published: 12 October 2010; BMJ 341 doi:10.1136/bmj.c5391
- Head To Head Published: 28 February 2008; BMJ 336 doi:10.1136/bmj.39493.489213.AD
- Analysis Published: 03 December 2008; BMJ 337 doi:10.1136/bmj.a2591
- Analysis Published: 04 February 2009; BMJ 338 doi:10.1136/bmj.b211
- Editorial Published: 13 September 2007; BMJ 335 doi:10.1136/bmj.39310.506308.AD
- Head To Head Published: 14 October 2011; BMJ 343 doi:10.1136/bmj.d6428
- Views & Reviews Published: 29 October 2013; BMJ 347 doi:10.1136/bmj.f6510
- Head To Head Published: 14 January 2014; BMJ 348 doi:10.1136/bmj.g171
- Analysis Published: 21 October 2015; BMJ 351 doi:10.1136/bmj.h5002
- Editorial Published: 28 November 2014; BMJ 349 doi:10.1136/bmj.g7197
- Analysis Published: 30 April 2018; BMJ 361 doi:10.1136/bmj.k1809
- Research Published: 03 November 2021; BMJ 375 doi:10.1136/bmj-2021-066576
See more
- NICE approves new cholesterol lowering drug after NHS strikes deal with manufacturerBMJ September 01, 2021, 374 n2143; DOI: https://doi.org/10.1136/bmj.n2143
- Restarting NHS cardiovascular care after covid-19BMJ July 27, 2021, 374 n1861; DOI: https://doi.org/10.1136/bmj.n1861
- Many more people could benefit from blood pressure lowering drugs, say researchersBMJ April 30, 2021, 373 n1120; DOI: https://doi.org/10.1136/bmj.n1120
- Two thirds of female cardiologists have experienced discrimination, survey findsBMJ March 17, 2021, 372 n748; DOI: https://doi.org/10.1136/bmj.n748
- Pulse oximetry may underestimate hypoxaemia in black patients, study findsBMJ December 21, 2020, 371 m4926; DOI: https://doi.org/10.1136/bmj.m4926
Cited by...
- The FDA-approved drugs ticlopidine, sertaconazole, and dexlansoprazole can cause morphological changes in C. elegans
- Ethical drug marketing criteria for the 21st century
- Bringing Vioxx back to market
- How do authors of systematic reviews deal with research malpractice and misconduct in original studies? A cross-sectional analysis of systematic reviews and survey of their authors
- Difficulty accessing data from randomised trials of drugs for heart failure: a call for action
- FDA Policy and Cardiovascular Medicine
- Efficacy And Safety Concerns Are Important Reasons Why The FDA Requires Multiple Reviews Before Approval Of New Drugs
- Medical journals and industry ties
- Should journals stop publishing research funded by the drug industry?
- Why I worry about large international studies
- Should journals sell reprints? Yes
- Data availability for industry sponsored trials: what should medical journals require?
- Improving Drug Safety Surveillance: Lessons From Rosiglitazone
- Policy Research: Using Evidence to Improve Healthcare Delivery Systems
- Relationships with the drug industry: More regulation, greater transparency
- What can we learn from drug marketing efficiency?
- MEDICINE: Moving Toward Transparency of Clinical Trials
- Has the hunt for conflicts of interest gone too far? Yes
- Direct to consumer advertising of drugs in Europe
- Use of Nonsteroidal Antiinflammatory Drugs: An Update for Clinicians: A Scientific Statement From the American Heart Association
- Entrepreneurship in the Medical Academy: Possibilities and Challenges in Commercialization of Research Discoveries